Approaches to evaluate the effect of renal impairment on drug exposure and best practice considerations for translating pharmacokinetic (PK) information into dose individualization instructions
Read MoreMAR 15 ACPS-CP
Model-informed drug development
Read MoreMAR 15 ACPS-CP
Model-informed drug development
Read MoreMAR 15 ACPS-CP
Model-informed drug development
Read MoreMAR 15 ACPS-CP
Model-informed drug development
Read More